Phase 3 Clinical Trials With Primary Completion Dates in February 2018
This is a list of Phase 3 trials with primary completion dates in February 2018 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| ANTH | Anthera Pharmaceuticals, Inc. | 2018-02-01 | Phase 3 | NCT03051490 | RESULT: Reliable, Emergent Solution Using Liprotamase Treatment |
| BHVN | Biohaven Pharmaceutical Holding Company Ltd. | 2018-02-01 | Phase 3 | NCT03237845 | Safety and Efficacy in Adult Subjects With Acute Migraines |
| CLSD | Clearside Biomedical, Inc. | 2018-02-01 | Phase 3 | NCT03097315 | Suprachoroidal Injection of CLS-TA in Subjects Non-infectious Uveitis |
| CLSD | Clearside Biomedical, Inc. | 2018-02-01 | Phase 3 | NCT02595398 | Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis |
| ENDP | Endo International plc | 2018-02-01 | Phase 3 | NCT01210352 | Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric Subjects |
| GRFS | Grifols, S.A. | 2018-02-01 | Phase 3 | NCT02604810 | Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency |
| GRFS | Grifols, S.A. | 2018-02-01 | Phase 3 | NCT02697292 | IVIG in Patients With VGKC Ab Associated Autoimmune Epilepsy |
| KMPH | KemPharm, Inc. | 2018-02-01 | Phase 3 | NCT03292952 | KP415 Classroom Study in Children (6-12 Years of Age) With ADHD |
| MESO | Mesoblast Limited | 2018-02-01 | Phase 3 | NCT02032004 | Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure. |
| MESO | Mesoblast Limited | 2018-02-01 | Phase 3 | NCT01854567 | P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies |
| ONTX | Onconova Therapeutics, Inc. | 2018-02-01 | Phase 3 | NCT01928537 | Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine |
| ONTX | Onconova Therapeutics, Inc. | 2018-02-01 | Phase 3 | NCT01241500 | Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts |
| PRAH | PRA Health Sciences, Inc. | 2018-02-01 | Phase 3 | NCT02817828 | E4 FREEDOM (Female Response Concerning Efficacy and Safety of Estetrol/Drospirenone as Oral Contraceptive in a Multicentric Study) - EU/Russia Study |